The depletion of FANCF gene results in the inhibition of FANCD2 monoubiquitination and the enhancement of sensitivity to DNA cross-linking agents (melphalan, cisplatin and mitomycin) in myeloma, ovarian and breast cancer cells [25–27]. This evidence concerns the gene FANCF and breast cancer.